Comparative effectiveness of first-line palbociclib plus letrozole versus letrozole alone for HR+/HER2− metastatic breast cancer in US real-world clinical practice

by Angela DeMichele, Massimo Cristofanilli, Adam Brufsky, Xianchen Liu, Jack Mardekian, Lynn McRoy, Rachel M. Layman, Birol Emir, Mylin A. Torres, Hope S. Rugo, Richard S. Finn
Published 2021-03-01

Infliximab for the treatment of patients with checkpoint inhibitor associated acute tubular interstitial nephritis

by Jamie S. Lin, Omar Mamlouk, Umut Selamet, Amanda Tchakarov, William F. Glass, Rahul A. Sheth, Rachel M. Layman, Ramona Dadu, Noha Abdel-Wahab, Maen Abdelrahim, Adi Diab, Cassian Yee, Ala Abudayyeh
Published 2021-01-01

Quantitative hormone receptor (HR) expression and gene expression analysis in HR+ inflammatory breast cancer (IBC) vs non-IBC

by Toshiaki Iwase, Kenichi Harano, Hiroko Masuda, Kumiko Kida, Kenneth R. Hess, Ying Wang, Luc Dirix, Steven J. Van Laere, Anthony Lucci, Savitri Krishnamurthy, Wendy A. Woodward, Rachel M. Layman, François Bertucci, Naoto T. Ueno
Published 2020-05-01

Exploratory analysis of immune checkpoint receptor expression by circulating T cells and tumor specimens in patients receiving neo-adjuvant chemotherapy for operable breast cancer

by Robert Wesolowski, Andrew Stiff, Dionisia Quiroga, Christopher McQuinn, Zaibo Li, Hiroaki Nitta, Himanshu Savardekar, Brooke Benner, Bhuvaneswari Ramaswamy, Maryam Lustberg, Rachel M. Layman, Erin Macrae, Mahmoud Kassem, Nicole Williams, Sagar Sardesai, Jeffrey VanDeusen, Daniel Stover, Mathew Cherian, Thomas A. Mace, Lianbo Yu, Megan Duggan, William E. Carson
Published 2020-05-01